The Pharma Data

OCTOBER 25, 2020

Furthermore, we will advance the field of native lung recovery and improve patient outcomes by collecting critical research data and developing and teaching best practices.”. This press release contains forward-looking statements. commercial availability expected in calendar year 2021. 14 days for Impella 5.0 and Impella 5.5

Cardiology 52

Cardiology FDA Approval Production Engineer 52

The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). Global Head of Cardiovascular, Renal and Metabolic Drug Development, Novartis. “As This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

RNA 52

RNA Trials Production Containment 52

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

FEBRUARY 26, 2021

However, it wasn’t until 1959 – 73 years and two major acquisitions later – that J&J developed its significant presence in the pharmaceutical industry. Its founder, Dr Paul Janssen, is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century. Where it all began.

Sales 125

Sales Production Pharma Companies Marketing 125

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Research and development (R&D) expense for the three and nine months ended September 30, 2020 were $10.2

Sales 40

Sales Production Cardiology Marketing 40

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. In addition, the cascades can also contain beta emissions.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

OCTOBER 14, 2020

Felker and Dr. Udelson join current advisors to support the development ofalfapump ® DSR for the management of fluid overload in patients with heart failure. The Sequana Medical management team is working closely with its advisors on the development of alfa pump DSR (Direct Sodium Removal). GHENT, Belgium, Oct.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 16, 2020

The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. of those who took aspirin alone developed heart-related illness, compared to 4.7% MONDAY, Nov.

Doctors 52

Doctors Doctor Cardiology Pharma Companies 52

The Pharma Data

OCTOBER 29, 2020

Research and Development. ALXN2060 (AG10) – Eidos: Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan. SOLIRIS – Neuromyelitis Optica Spectrum Disorder (NMOSD): A Phase 2/3 study of SOLIRIS in children and adolescents with NMOSD is underway. Forward-Looking Statement.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

The Pharma Data

SEPTEMBER 15, 2020

(NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

APRIL 26, 2021

At present, drug development operations are continuing with manageable disruptions (see the Innovation Review Section of the Condensed Interim Financial Report for further information), with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions. Diovan Group.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

MAY 13, 2021

Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease. Experimental Diabetes Research. Fructose as a key player in the development of fatty liver disease. How does brain insulin resistance develop in Alzheimer’s disease?

Insulin 52

Insulin Production Hormones Medicine 52